Modelling direct healthcare costs for screening and treatment of retinopathy of prematurity among infants born at gestational age <24 weeks: findings from a Swedish cohort.

ABSTRACT:

Objective

Sweden has a long-standing tradition of actively managing infants born extremely preterm at 22-23 weeks' gestational age. This study analyses screening and treatment pathways for retinopathy of prematurity (ROP) in these infants, assessing costs and health outcomes to develop a model of direct healthcare costs.

Method and analysis

The cohort included all 399 infants born at 22-23 weeks in Sweden (2007-2018) who underwent ROP screening, recorded in the national ROP registry SWEDROP. A health economic model estimated costs based on three primary pathways: (1) no sight-saving treatment, (2) laser as initial treatment and (3) anti-vascular endothelial growth factor (anti-VEGF) as initial treatment. Pathways 2 and 3 were further divided into single and multiple treatmen

SUBMITTER: Lofqvist C 

PROVIDER: S-EPMC12766756 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature